Treatment with 9cisRA (2 mg/kg/day for 180 days) in 22 dogs with CD led to a significant reduction in plasma ACTH and α-MSH at 90 days of treatment compared to baseline values (p < 0.01), and reduced corticotroph tumor size at 180 days with improved clinical signs and increased survival time [44]. The gene discussed is POMC; the disease is neoplasm.